Surgical Valve Replacement/Repair
Treatment for Endocarditis
Effectiveness
93%
Safety Score
45%
Clinical Trials
2
Participants
5K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
45
DangerousModerateSafe
Treatment Details
Time to Effect
Immediate mechanical correction
Treatment Duration
Acute intervention + lifelong follow-up
Evidence Quality
HIGHNumber Needed to Treat (NNT)
3(Treat 3 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
7(Treat 7 patients to see 1 additional serious adverse event)
Confidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$0
Monitoring:$200,000
Side Effect Mgmt:$30,000
Total Annual:$230,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$45,000/QALY
QALYs Gained
5
Outcome-Based Costs
Cost per Responder
$255,556
Cost per Remission
$270,588
Comparison vs Medical management alone
Cost Difference
+$100,000/year
More expensive
QALY Difference
+3.00 QALYs
Better outcomes
Dominance
No dominance
Surgical Valve Replacement/Repair Outcomes
for Endocarditis
Efficacy Outcomes
Overall Effectiveness
+93%
Response Rate
+90%
Remission Rate
+85%
Common Side Effects
Bleeding/Hemorrhage
+15%
Stroke/Neurological events
+6%
Acute Kidney Injury
+10%
Post-operative infection
+3.5%
Arrhythmias
+20%
Death
+10%
Active Clinical Trials
1 active trial recruiting for Surgical Valve Replacement/Repair in Endocarditis
Infective Endocarditis Surgery Using Conventional Prosthetic Valves Versus Cryopreserved Aortic Homograft
NCT05253469ENROLLING BY INVITATION
760 participants
OBSERVATIONAL
Saint-Denis, France
Started: Jan 1, 2005
Completed Clinical Trials
1 completed trial for Surgical Valve Replacement/Repair in Endocarditis
Early Surgery Versus Conventional Treatment in Infective Endocarditis
NCT00750373COMPLETEDPHASE4
76 participants
INTERVENTIONAL
Seoul, South Korea +1 more
Started: Sep 1, 2006